Extrachromosomal DNA

Boundless Bio Announces Educational Session on Extrachromosomal DNA (ecDNA) at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Monday, May 17, 2021
General Health, Health, Science, Research, Oncology, Cancer, Clinical medicine, Medicine, Oncology, Carcinogenesis, DNA, Chromosomes, Cancer treatments, Extrachromosomal DNA, Oncogene, Centromere, Chemotherapy

b'Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA lacking centromeres but containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.

Key Points: 
  • b'Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA lacking centromeres but containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.
  • ecDNA replicate within cancer cells and can be passed to daughter cells asymmetrically during cell division, thereby constituting a primary driver of focal gene amplification and copy number heterogeneity in cancer.
  • By leveraging the plasticity afforded by ecDNA, cancer has the ability to increase or decrease copy number of select oncogenes located on ecDNA to enable survival under selective pressures, including chemotherapy, targeted therapy, immunotherapy, or radiation, making ecDNA one of cancer cells\xe2\x80\x99 primary mechanisms of recurrence and treatment resistance.
  • ecDNA are not found in healthy cells but are present in many solid tumor cancers.

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Wednesday, March 31, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, DNA, Extrachromosomal DNA, Cancer, Oncology, Branches of biology, Medical specialties, Health, Medical genetics, Carcinogenesis, ecDNA, Boundless Bio

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021.
  • ecDNA replicate within cancer cells and can be passed to daughter cells asymmetrically during cell division, thereby constituting a primary driver of focal gene amplification and copy number heterogeneity in cancer.
  • They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect 2021 Conference

Retrieved on: 
Wednesday, January 6, 2021
Biotechnology, Genetics, Health, Oncology, DNA, Boundless, Extrachromosomal DNA, Cancer

Boundless Bio , a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will present at the 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright BioConnect 2021 Conference.

Key Points: 
  • Boundless Bio , a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will present at the 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright BioConnect 2021 Conference.
  • Presentation details are as follows:
    Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005216/en/

Boundless Bio Presents Research Showcasing its Imaging and Single-Cell Sequencing Platform for Extrachromosomal DNA (ecDNA) Detection at the 2020 American Society of Human Genetics (ASHG) Virtual Annual Meeting

Retrieved on: 
Monday, October 26, 2020
Oncology, Health, Genetics, Research, Science, Biotechnology, DNA, Biology, Carcinogenesis, Extrachromosomal DNA, Life sciences, Biotechnology, Branches of biology, Oncogene, Cancer, Single cell sequencing, Extrachromosomal circular DNA, Double minute

Boundless Bio , a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today will present research highlighting powerful components of its proprietary Spyglass platform at the 2020 American Society of Human Genetics (ASHG) Annual Meeting.

Key Points: 
  • Boundless Bio , a biotechnology company developing innovative therapeutics directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today will present research highlighting powerful components of its proprietary Spyglass platform at the 2020 American Society of Human Genetics (ASHG) Annual Meeting.
  • The poster, titled A Robust Imaging and Single-Cell Sequencing Platform to Characterize Tumor Extrachromosomal DNA (ecDNA) in Response to Therapeutic Intervention , describes elements of Boundless Bios broad platform for interrogating ecDNA biology.
  • Tumors driven by oncogene amplification are aggressive, have poor prognosis, and have proven elusive for targeted therapies.
  • Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.

Boundless Bio Announces Poster Presentation at the 2020 American Society of Human Genetics (ASHG) Virtual Annual Meeting

Retrieved on: 
Wednesday, October 21, 2020
Biotechnology, General Health, Health, Genetics, Oncology, DNA, Medicine, Health, Clinical medicine, Carcinogenesis, Oncology, Extrachromosomal DNA, Draft:Boundless Bio, Cancer, Oncogene, Tumour heterogeneity, Extrachromosomal circular DNA, ecDNA, Boundless Bio

Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.

Key Points: 
  • Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.
  • ecDNA rapidly replicate within cancer cells, causing high numbers of oncogene copies and can be passed to daughter cells asymmetrically during cell division, driving tumor heterogeneity.
  • They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio to Present at the Citi 15th Annual BioPharma Virtual Conference

Retrieved on: 
Thursday, September 3, 2020
Oncology, Health, Genetics, Other Health, Pharmaceutical, Biotechnology, DNA, Draft:Boundless Bio, Extrachromosomal DNA, Cancer, Oncology, Boundless

Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced it will present a corporate overview at Citis 15th Annual BioPharma Virtual Conference.

Key Points: 
  • Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced it will present a corporate overview at Citis 15th Annual BioPharma Virtual Conference.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005213/en/

Boundless Bio Announces Publication in Nature Genetics Detailing the Association Between Extrachromosomal DNA-Based Oncogene Amplification and Poor Cancer Outcomes

Retrieved on: 
Monday, August 17, 2020
Genetics, Health, Oncology, DNA, Draft:Boundless Bio, Branches of biology, Medical genetics, Extrachromosomal DNA, Biology, Applied genetics, Biotechnology, Cancer, Oncogenomics, ecDNA, Boundless Bio, Boundless Bio’s Spyglass™ Platform

Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced research published in the journal Nature Genetics that demonstrates that ecDNA-based oncogene amplification drives poor outcomes for patients across many cancer types.

Key Points: 
  • Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced research published in the journal Nature Genetics that demonstrates that ecDNA-based oncogene amplification drives poor outcomes for patients across many cancer types.
  • Ludwig Professor of Cancer Genomics and Genetics, Stanford University; and Roel Verhaak, Ph.D., Professor and Associate Director of Computational Biology, The Jackson Laboratory.
  • In addition, patients whose cancers carried ecDNA had significantly shorter survival, even when controlled for tissue type, than patients whose cancers were not driven by ecDNA-based oncogene amplification.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Scientific Co-Founder Paul Mischel to Present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

Retrieved on: 
Tuesday, June 16, 2020
Oncology, Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Causes of death, Extrachromosomal DNA, Health, Medicine, Paul Mischel, Cancer, DNA, Oncogene, Extrachromosomal circular DNA, ecDNA, Boundless Bio

Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that scientific co-founder, Paul Mischel, M.D., will be lecturing on the foundational role that ecDNA plays in driving resistance to standard of care therapies at the American Association for Cancer Research (AACR) Virtual Annual Meeting II , held June 22-24, 2020.

Key Points: 
  • Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that scientific co-founder, Paul Mischel, M.D., will be lecturing on the foundational role that ecDNA plays in driving resistance to standard of care therapies at the American Association for Cancer Research (AACR) Virtual Annual Meeting II , held June 22-24, 2020.
  • Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes that are located outside cells chromosomes and can make many copies of themselves.
  • ecDNA rapidly replicate within cancer cells, causing high numbers of oncogene copies, a trait that can be passed to daughter cells in asymmetric ways during cell division.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Presents Data Assessing the Relationship Between Extrachromosomal DNA and Biomarker Signatures Associated with Response to Checkpoint Inhibitors in Gastric Cancer at the 2020 ASCO Virtual Annual Meeting

Retrieved on: 
Friday, May 29, 2020
Oncology, Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, DNA, Biotechnology, Extrachromosomal DNA, Cancer, Biology, ecDNA, Boundless Bio

The ecDNA-positive subtype also had lower PD-L1 expression than all the other molecular subtypes but the GS and CIN subtypes.

Key Points: 
  • The ecDNA-positive subtype also had lower PD-L1 expression than all the other molecular subtypes but the GS and CIN subtypes.
  • Boundless Bio is developing novel therapeutic strategies directed to mechanisms critical for ecDNA function in cancer.
  • Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells chromosomes and can make many copies of themselves.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Retrieved on: 
Wednesday, May 13, 2020
Biotechnology, Genetics, Health, Oncology, DNA, Extrachromosomal DNA, Cancer, Medicine, Oncogene, Branches of biology, Health, Double minute, Extrachromosomal circular DNA, ecDNA, Boundless Bio

Due to the virtual format, all oral, poster, and poster discussion sessions, as well as track-based Clinical Science Symposia, will be available on demand, beginning May 29 at 8 a.m. EDT, for registered attendees of the conference.

Key Points: 
  • Due to the virtual format, all oral, poster, and poster discussion sessions, as well as track-based Clinical Science Symposia, will be available on demand, beginning May 29 at 8 a.m. EDT, for registered attendees of the conference.
  • Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells chromosomes and can make many copies of themselves.
  • They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.